Hypertension Guidelines: Is It Time to Reappraise Blood Pressure Thresholds and Targets?: Position Statement of the Latin American Society of Hypertension

Hypertension

Volumn 68, Issue 2, 2016, Pages 257-262

  López Jaramillo, Patricio ^a   Coca, Antonio ^b   Sánchez, Ramiro ^c   Zanchetti, Alberto ^d  

^a UNIVERSIDAD DE SANTANDER   (Colombia)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGED; AMERICAN; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DECISION MAKING; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; LATIN AMERICAN MEDICINE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; DRUG EFFECTS; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; GUIDELINES AS TOPIC; HUMANS; HYPERTENSION;

EID: 84974728200     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07738     Document Type: Review

References (46)

1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. doi: 10.1097/01.hjh.0000431740.32696.cc.
2. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285-2295. doi: 10.1097/HJH.0000000000000378.
3. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs-overview and meta-analyses. J Hypertens. 2015;33:1321-1341. doi: 10.1097/HJH.0000000000000614.
4. Zanchetti A. Evidence and wisdom: recommendations for forthcoming guidelines. J Hypertens. 2011;29:1-3. doi: 10.1097/ HJH.0b013e328341fb35.
5. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. doi: 10.1001/jama.2013.284427.
6. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels-overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2296-2304. doi: 10.1097/ HJH.0000000000000379.
7. Wei Y, Jin Z, Shen G, Zhao X, Yang W, Zhong Y, Wang J. Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. J Clin Hypertens (Greenwich). 2013;15:420-427. doi: 10.1111/jch.12094.
8. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-2116.
9. Lonn EM, Bosch J, López-Jaramillo P, et al; HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009-2020. doi: 10.1056/ NEJMoa1600175.
10. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009;27:923-934. doi: 10.1097/HJH.0b013e32832aa6b5.
11. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012;8:CD006742. doi: 10.1002/14651858.CD006742.pub2.
12. National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults. http:// www.nice.org.uk/guidance/CG127.
13. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3-15. doi: 10.1097/ HJH.0000000000000065.
14. Zanchetti A. Do we over treat mild hypertension? Expert Opin Pharmacother. 2015;16:1121-1126. doi: 10.1517/14656566.2015.1040761.
15. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A; Chairpersons and Section Coordinators of the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC). Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. J Hypertens. 2014;32:1551-1552. doi: 10.1097/ HJH.0000000000000275.
16. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898. doi: 10.1056/NEJMoa0801369.
17. Beckett N, Peters R, Leonetti G, Duggan J, Fagard R, Thijs L, Narkiewicz K, McCormack T, Banya W, Fletcher A, Bulpitt C; HYVET Study Group. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens. 2014;32:1478-87; discussion 1487. doi: 10.1097/HJH.0000000000000195.
18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
19. DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008; 31:1007-1014.
20. The NAVIGATOR study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Eng J Med. 2010; 362:1477-1490.
21. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-1097. doi: 10.1046/j.1523-1755.2002.00213.x.
22. Zanchetti A, Liu L, Mancia G, et al. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens. 2014;32:1741-1750. doi: 10.1097/HJH.0000000000000253.
23. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575-1585.
24. López-Jaramillo P, Sánchez RA, Diaz M, et al.; Latin America Expert Group. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. J Hypertens. 2013;31:223-238. doi: 10.1097/HJH.0b013e32835c5444.
25. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003;34:2741-2748. doi: 10.1161/01.STR.0000092488.40085.15.
26. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke. 1993; 24:543-548.
27. PATS Collaborating Group. Post-stroke antihypertensive treatment study: a preliminary result. Chin Med J. 1995; 108:710-717.
28. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355:253-259.
29. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
30. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1:485-489.
31. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974; 229:409-418.
32. Eriksson S, Olofsson BO, Wester PO. Atenolol in secondary prevention after stroke. Cerebrovasc Dis. 1995; 5:21-25.
33. Yusuf S, Diener HC, Sacco RL, et al; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-1237. doi: 10.1056/NEJMoa0804593.
34. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372: 1174-1183.
35. Diener HC. Preventing stroke: the PROFESS, ONTARGET, and TRASCEND trial programs. J Hypertens. 2009;27(suppl 5):S31-S36.
36. Benavent OR, Coffey CS, Convit R, et al; SPS3 Study Group. Blood pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-512.
37. Odden MC, McClure LA, Sawaya BP, White CL, Peralta CA, Field TS, Hart RG, Benavente OR, Pergola PE. Achieved blood pressure and outcomes in the secondary prevention of small subcortical strokes trial. Hypertension. 2016;67:63-69. doi: 10.1161/HYPERTENSIONAHA.115.06480.
38. Zanchetti A, Liu L, Mancia G, et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens. 2014;32:1888-1897. doi: 10.1097/ HJH.0000000000000254.
39. Zanchetti A, Liu L, Mancia G, et al; ESH-CHL-SHOT trial investigators. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens. 2016;34:393-396. doi: 10.1097/HJH.0000000000000853.
40. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension. 2016;67:808-812. doi: 10.1161/ HYPERTENSIONAHA.116.07257.
41. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels-updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613-622. doi: 10.1097/HJH.0000000000000881.
42. Thomopoulos C, Parati G. Zanchetti A. Effects of blood pressure lowering treatment in hypertension. 8. Outcome reductions versus discontinuations due to adverse drug events-meta-analyses of randomized trials. J Hypertens. In press.
43. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
44. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703-713.
45. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk-overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2305-2314. doi: 10.1097/HJH.0000000000000380.
46. Yusuf S, Lonn E, Pais P, et al.; HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374:2032-2043. doi: 10.1056/NEJMoa1600177.